BRIEF—Karyopharm applies for US approval for multiple myeloma candidate

East Coast, USA-based drugmaker Karyopharm has applied to the US Food and Drug Administration for accelerated approval for its multiple myeloma candidate selinexor.

The firm wants to market selinexor as a new treatment for patients with penta-refractory multiple myeloma, who have experienced disease progression after multiple lines of therapy.

Selinexor has received both Orphan Drug and Fast Track designations from the FDA for this indication.